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Autism spectrum disorder (ASD) is defined by persistent deficits in social communication/interaction and stereotypic behaviors 
with many diagnosed persons experiencing a developmental regression at >1 year‑old. It was hypothesized that progressive 
childhood encephalopathy is an important etiological factor in ASD pathogenesis. This hypothesis‑testing study examined 
the relationship between diagnosed childhood encephalopathy and ASD. The Independent Healthcare Research Database is 
composed of de‑identified linked eligibility and claim healthcare records prospectively generated from the Florida Medicaid 
system. A cohort of 101,736 persons eligible for Florida Medicaid from 1990‑2009 and continuously eligible with ≥10 outpatient 
office visits during the 120 month period following birth were examined using SAS software. There were 1,397 persons (7,223 
person‑years) in the ASD diagnosed cohort and 100,339 persons (980,786 person‑years) in the undiagnosed cohort. The 
incidence rate of encephalopathy was examined using Cox proportional hazards ratio models. In the ASD cohort relative to the 
undiagnosed cohort, a significantly increased incidence rate of diagnosed encephalopathy was observed in the unadjusted and 
adjusted models. The risk for an encephalopathy diagnosed at >1 year‑old was greater than for an encephalopathy diagnosed 
at <1 year‑old. This study provides important new evidence supporting the hypothesis that a significant number of children with 
an eventual ASD diagnosis experience a progressive childhood encephalopathy diagnosed at >1 year‑old.
Key words: autistic, cohort, encephalopathy, neurodevelopmental, PDD
INTRODUCTION
Autism spectrum disorder (ASD) is defined by per‑
sistent deficits in social communication and social 
interaction, and restricted, repetitive patterns of be‑
havior, interests, or activities (American Psychiatric 
Association, 2013). Although an ASD diagnosis is de‑
fined behaviorally by the American Psychiatric Asso‑
ciation (APA), other features, more physical or health 
related, are associated with an ASD diagnosis (Geier 
et al., 2012; Kern et al., 2014a). Among the most com‑
mon are gastrointestinal disturbances=48%, inconti‑
nence=57%, sleep problems=57%, eating disorders=94%, 
hyperactivity=67%, lethargy=26%, sensory processing 
problems=85%, anxiety/fear=74%, behavioral prob‑
lems=89%, and obsessive‑compulsive behaviors=92% 
(Geier et al., 2012).
The exact etiology of ASD remains under debate, but 
some investigators suggested that the etiology of ASD 
is genetic in origin, and that the disorder is heritable 
with complex inheritance and genetic heterogeneity 
(AlSagob et al., 2015). High resolution genetic evalu‑
ations using chromosomal microarray, chromosom‑
al karyotype, and Fragile X DNA testing revealed that 
approximately 80% of children with ASD have normal 
genetic test results (Shen et al., 2010; Geier et al., 2016). 
Of the remaining 20%, approximately half were of var‑
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ious polymorphisms of unknown significance, and the 
other half were de novo mutations with little to no 
commonality (<10% of persons diagnosed with an ASD). 
As a consequence, direct genetic causal factors for an 
ASD diagnosis are identifiable in only a limited number 
of persons diagnosed with an ASD.
By contrast, other investigators hypothesized that 
progressive childhood encephalopathy through a neu‑
rodegenerative pathway is an important etiological 
factor in ASD pathogenesis (Kern et al., 2013). In sup‑
port of their hypothesis, these investigators described 
that on a clinical basis a significant number of children 
diagnosed with an ASD were observed to undergo de‑
velopmental regression manifested by a loss of ver‑
bal, nonverbal, and social abilities starting at about 1 
year‑old. Overall, it was described by these investiga‑
tors that 15% to 62% of persons diagnosed with an ASD 
underwent regression. These investigators suggested 
that developmental regression among children diag‑
nosed with an ASD was symptomatic of childhood en‑
cephalopathy (Kern et al., 2014a; 2014b).
In order to quantitatively evaluate the aforemen‑
tioned hypothesis, the present hypothesis‑testing ep‑
idemiological study evaluated the incidence rate of 
childhood encephalopathy diagnoses among persons 
diagnosed with an ASD in comparison to persons not 
diagnosed with an ASD. In addition, the potential im‑
pact of the age on the incidence rate of encephalopa‑
thy diagnosis among persons diagnosed with an ASD as 
compared to persons not diagnosed with an ASD was 
considered.
METHODS
Independent Healthcare Research Database (IHRD)
The Independent Healthcare Research Database 
(IHRD) is composed of de‑identified healthcare records 
generated from the Florida Medicaid system. The data 
contained within the IHRD were obtained from the 
Agency for Health Care Administration (AHCA) of the 
state of Florida and included eligibility and claim files. 
It is possible to link a person’s eligibility and claim re‑
cords by a unique recipient identifier code. The eligi‑
bility records included detailed information for each 
person regarding their month and year of enrollment, 
gender, date of birth, and county level residency. The 
claims records included detailed information for each 
person regarding their diagnosis status using the In‑
ternational Code for Disease, 9th revision (ICD‑9) codes, 
healthcare procedure codes (medical, dental, etc.), and 
administered drugs using National Drug Codes (NDC). 
The data in the IHRD were assembled and accessed un‑
der approval by the Liberty Institutional Review Board 
(IRB) (Deland, FL). The SAS system for Windows, ver‑
sion 9.4 (Cary, NC, USA) running on a 64‑bit based PC 
with dual core Intel® (Santa Clara, CA, USA) Xeon® CPU 
x5680 at 3.33 GHz, 6 cores, and 12 logical processors, 
with 44.0 GB of RAM, and utilizing Microsoft (Redmond, 
WA, USA) Windows 7 Ultimate operating system was 
used to examine the IHRD.
Study Participants
Fig. 1 presents a schematic flowchart of the IHRD 
data examined in the present study. A cohort of 
8,440,941 persons of all ages with no changes or missing 
genders or dates of birth and eligible at specific times 
for Florida Medicaid from July 1990 through June 2009 
was initially evaluated in this study. Among this co‑
hort, a total of 1,871,728 persons were eligible for Flor‑
ida Medicaid from their date of birth, and among those 
persons a total of 193,453 persons were continuously 
eligible for Florida Medicaid for 120 months following 
birth. Finally, among the cohort of 193,453 persons con‑
tinuously eligible for Florida Medicaid for 120 months 
following birth, a sub‑cohort of 101,736 persons with 
≥10 outpatient office visits during the 120 month peri‑
od following birth was identified.
Exposures
The exposure variable examined in this study 
was identified from the ICD‑9 codes filed on claims 
for each cohort member examined. The ICD‑9 codes 
examined included: autistic disorder, current or ac‑
tive state (299.00) or other specified pervasive devel‑
opmental disorders, current or active state (299.80). 
Only persons diagnosed with at least one of the afore‑
mentioned outcomes were members of the ASD diag‑
nosed cohort, and persons not diagnosed with either 
of the aforementioned outcomes were members of 
the undiagnosed cohort (not diagnosed with an ASD). 
Among those diagnosed with an ASD, the date of ser‑
vice for the first claim in chronological order with an 
ICD‑9 code specifying an ASD was assumed to be the 
date of onset of the disorder. Overall, it was observed 
that 1,397 persons were in the ASD diagnosed cohort 
and 100,339 persons were in the undiagnosed cohort.
Outcomes
The outcome variable examined in this study was 
identified from the ICD‑9 codes filed on claims for each 
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cohort member examined. All encephalopathy‑relat‑
ed diagnoses (code: 348.3x) were examined, including: 
encephalopathy not elsewhere classified (348.3), en‑
cephalopathy unspecified (348.30), metabolic enceph‑
alopathy (348.31), and other encephalopathy (348.39). 
Persons were considered to have an encephalopathy if 
they had any of the encephalopathy‑related diagnoses, 
and persons were not considered to have encephalopa‑
thy if they did not have any of the encephalopathy‑re‑
lated diagnoses during the study period examined. 
Among those with an encephalopathy diagnosis, the 
date of service for the first claim in chronological or‑
der with an encephalopathy diagnosis was assumed to 
be the date of onset of an encephalopathy. Overall, it 
was observed that 3,512 persons were diagnosed with 
encephalopathy in the undiagnosed cohort. In the ASD 
diagnosis cohort, a total of 554 persons were diagnosed 
with encephalopathy, but only 313 were diagnosed with 
an encephalopathy before their ASD diagnosis. Only 
those persons diagnosed with an encephalopathy be‑
fore their ASD diagnosis were counted as having an en‑
cephalopathy diagnosis in this study.
Statistical analyses
In all statistical analyses, the statistical package 
in SAS was utilized, and a two‑sided p‑value<0.05 was 
considered statistically significant. The null hypothesis 
was that the incidence rate of encephalopathy diagno‑
sis would have no relationship with an ASD diagnosis.
A regression analysis of encephalopathy diagnosis 
based on the Cox proportional hazards model was used 
to evaluate the incidence rate of encephalopathy diag‑
noses among those persons in the ASD diagnosed co‑
hort as compared to the undiagnosed cohort. Ties in 
the failure times were handled using the exact method. 
In the undiagnosed cohort, person‑years of follow‑up 
began on the date of birth and continued until the end 
of eligibility (a maximum of 120 months after birth) or 
until the date of the first encephalopathy diagnosis. In 
the ASD diagnosed cohort, person‑years of follow‑up 
began on the date of birth and continued until an ASD 
diagnosis was made (a maximum of 120 months after 
birth) or until the date of the first encephalopathy di‑
agnosis. In addition, the potential impact of the age of 
Fig. 1. A schematic flowchart of the data examined in the present study.
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encephalopathy diagnosis was examined. Specifically, 
modeling was constructed to evaluate the impact of age 
of an encephalopathy by examining those persons di‑
agnosed with an encephalopathy at <1 year of age and 
>1 year of age. All models were constructed without ad‑
justment for covariates (Model I) and with adjustment 
for the covariates of gender, date of birth, and county 
of residence (Model II).
RESULTS
Table I displays the demographic characteristics 
of the persons evaluated in this study. Overall, there 
were a total 1,397 persons in the ASD diagnosed, cohort 
contributing a total of 7,223 person‑years and 100,339 
persons in the undiagnosed, cohort contributing a to‑
tal of 980,786 person‑years. The gender distribution in 
the ASD diagnosed cohort (male/female ratio=3.2) was 
greater than the undiagnosed cohort (male/female ra‑
tio=1.12). The mean date of birth was similar for the 
ASD diagnosed and undiagnosed cohorts. The inci‑
dence rate of diagnosed encephalopathy was signifi‑
cantly higher at 22.4% (95% confidence interval=20.25 
to 24.61) in the ASD diagnosed cohort as compared to 
3.50% (95% confidence interval=3.39 to 3.62) in the un‑
diagnosed cohort.
Table II shows the demographic characteristics of 
the 3,825 persons diagnosed with an encephalopathy. 
Slightly more males than females were diagnosed with 
an encephalopathy (male/female ratio=1.5) with the 
ratio being higher than those observed in the undi‑
agnosed cohort but lower than in the ASD diagnosed 
cohort. The mean date of birth for persons diagnosed 
with an encephalopathy (1995) was similar in the ASD 
diagnosed and undiagnosed cohorts.
Table III reveals the Cox proportional hazards model 
results examining the relationship between the diag‑
nosed incidence rates of encephalopathy among those 
persons with an ASD diagnosis in comparison to those 
persons not diagnosed with an ASD. It was observed 
when comparing the ASD diagnosed cohort relative to 
the undiagnosed cohort that the hazard ratio for the 
incidence rate of encephalopathy diagnosis was sig‑
nificantly increased in both the unadjusted (hazard 
ratio=9.65) and adjusted (hazard ratio=8.98) models. It 
was also observed in the adjusted model that gender 
and county of residence were significant covariates.
Fig. 2 is a Cox proportional hazards survival plot eval‑
uating the incidence rate of diagnosed encephalopathy 
cases over the age in years for persons were examined in 
the ASD and undiagnosed cohorts. The plot reveals that 
in the initial period (< 3 months) there was a similar inci‑
dence rate of diagnosed encephalopathy among the ASD 
and undiagnosed cohorts (adjusted hazard ratio=1.79, 
p=0.085). The incidence rate of diagnosed encephalop‑
athy cases subsequently steadily increased in the ASD 
diagnosed cohort relative to the undiagnosed cohort, so 
that by the end of the follow‑up period at 10 years, there 
was more than a 10‑fold increase in the incidence rate 
of diagnosed encephalopathy cases in the ASD diagnosed 
cohort relative to the undiagnosed cohort.
Table IV reveals the impact of age on the incidence 
rate of encephalopathy diagnosis in the ASD diagnosed 
and undiagnosed cohorts. It was observed when com‑
paring the ASD diagnosed cohort to the undiagnosed 
cohort that the incidence rate of diagnosed encepha‑
lopathy at >1 year‑old (unadjusted hazard ratio=13.22 
or adjusted hazard ratio=12.30) relative to the inci‑
dence rate of diagnosed encephalopathy at <1 year‑old 
(unadjusted hazard ratio=3.91 or adjusted hazard ra‑
tio=3.65), the risk was significantly increased.
Table I. Demographic characteristics of the cohorts examined in this study1.
Parameter Examined ASD Diagnosed Cohort
2
(n=1,397)
Undiagnosed Cohort3
(n=100,339)
Person‑Years 7,223 980,786
Gender (%)
Male 1,060 (75.88%) 53,094 (52.91%)
Female 337 (24.12%) 47,245 (47.09%)
Date of Birth
mean ± std (range) 1995±2.6 (1990–1999) 1995±2.6 (1990–1999)
Number Diagnosed with Encephalopathy
(ICD‑9 Code: 348.3x) 313
4 3,512
ASD = Autism Spectrum Disorder; ICD‑9 = International Code of Disease, 9th revision; std = standard deviation. 1 All persons examined in this study were enrolled from their date 
of birth for 120 consecutive months. All persons had non‑changing dates of birth and gender status. All persons had ≥ 10 outpatient office visits. 2 Persons diagnosed with an 
ASD (ICD‑9 codes of 299.00 or 299.80). 3 Persons were not diagnosed with an autism spectrum disorder (ICD‑9 codes 299.00 or 299.80). 4 A total of 241 persons with a diagnosed 
encephalopathy post‑ASD diagnosis were excluded.
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Table II. Demographic summary of the persons diagnosed with an encephalopathy evaluated in this study1.
Parameter Examined Persons Diagnosed with an Encephalopathy(n=3,825)
Gender (%)
Male 2,282 (59.66%)
Female 1,543 (40.34%)
Date of Birth
mean ± std (range) 1995±2.6 (1990–1999)
Age in Years of Initial Diagnosis
mean ± std (range) 3.61±2.91 (0–10)
Encephalopathy Diagnosis Categories
Encephalopathy not elsewhere classified (348.3) 3,538 (92.50%)
Encephalopathy unspecified (348.30) 259 (6.77%)
Metabolic encephalopathy (348.31) 1 (0.03%)
Other encephalopathy (348.39) 27 (0.70%)
1 All persons examined in this study were enrolled from their date of birth for 120 consecutive months. All persons had non‑changing dates of birth and gender status.  
All persons had ≥10 outpatient office visits.
Fig. 2. A Cox proportional hazards survival plot evaluating the incidence rate of encephalopathy diagnosed over the period examined in the ASD diagnosed 
cohort (1) in comparison to the undiagnosed cohort (0).
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Table III. Cox proportional hazards model results examining the incidence rate of encephalopathy diagnoses in the ASD diagnosed and undiagnosed cohorts.
Model Outcome Variable Hazard Ratio 95% CI p‑value χ2
I
Encephalopathy 
(Diagnosed at any age)
ASD (Diagnosed vs. Undiagnosed) 9.65 8.59 to 10.84 <0.0001 1,449
II
Encephalopathy
(Diagnosed at any age)
ASD (Diagnosed vs. Undiagnosed) 8.98 7.98 to 10.11 <0.0001 1,325
Gender (Female vs. Male) 0.82 0.76 to 0.87 <0.0001 38
County of Residence 0.99 0.99 to 0.99 <0.0001 207
Date of Birth 1.00 1.00 to 1.00 0.92 0.01
Italicized results are statistically significant. Model I = unadjusted, Model II = adjusted for gender, county of residence, and date of birth. CI=confidence interval
Table  IV. An evaluation of the impact of the age of an encephalopathy diagnosis in ASD diagnosed and undiagnosed cohorts using Cox proportional 
hazards modeling.
Model Outcome Variable Hazard Ratio 95% CI p‑value χ2
I
Encephalopathy
(Diagnosed at <1 year‑old)
ASD (Diagnosed vs. Undiagnosed) 3.91 2.94 to 5.19 <0.0001 88
Encephalopathy
(Diagnosed at >1 year‑old)
ASD (Diagnosed vs. Undiagnosed) 13.22 11.62 to 15.03 <0.0001 1,547
II
Encephalopathy
(Diagnosed at <1 year‑old)
ASD (Diagnosed vs. Undiagnosed) 3.65 2.74 to 4.87 <0.0001 78
Gender (Female vs. Male) 0.91 0.80 to 1.03 0.14 2.20
County of Residence 0.99 0.99 to 0.99 <0.0001 22
Date of Birth 1.00 1.00 to 1.00 0.018 5.63
Encephalopathy
(Diagnosed at >1 year‑old)
ASD (Diagnosed vs. Undiagnosed) 12.30 10.8 to 14.02 <0.0001 1,423
Gender (Female vs. Male) 0.78 0.73 to 0.85 <0.0001 40
County of Residence 0.99 0.99 to 0.99 <0.0001 192
Date of Birth 1.00 1.00 to1.00 0.13 2.27
Italicized results are statistically significant. Model I = unadjusted, Model II = adjusted for gender, county of residence, and date of birth. CI=confidence interval.
72 Kern et al. Acta Neurobiol Exp 2020, 80: 66–75
DISCUSSION
The results of this retrospective longitudinal cohort 
study of prospectively collected healthcare data pro‑
vide important and compelling new epidemiological 
quantitative data regarding the relationship between 
progressive childhood encephalopathy diagnoses and 
the long‑term risk of an ASD diagnosis. It was revealed 
among persons with an ASD diagnosis relative to per‑
sons not diagnosed with an ASD that the incidence 
rate of diagnosed encephalopathy was significantly 
increased and the relationship was significantly me‑
diating by age of an encephalopathy diagnosis. Name‑
ly, among persons diagnosed with an ASD relative to 
persons not diagnosed with an ASD, the incidence rate 
of diagnoses encephalopathy made at >1 year‑old were 
significantly increased relative to the incidence rate of 
diagnoses encephalopathy made at <1 year‑old. Finally, 
the observed effects remained significant when con‑
sidering such covariates as gender, date of birth, and 
county of residence.
A literature search identified only one epidemio‑
logical study that examined the relationship between 
childhood encephalopathy and the subsequent risk for 
an ASD diagnosis (Badawi et al., 2006). In that study, 
Badawi et al (2006), examined 276 cases with an en‑
cephalopathy and 564 randomly selected controls from 
Western Australia. All cases and controls underwent 
comprehensive neurobehavioral and cognitive fol‑
low‑up at 3 and 5 years of age. At 5 years‑old, it was 
observed that 5% of cases with an encephalopathy were 
diagnosed with an ASD, whereas only 0.8% of controls 
were diagnosed with an ASD. Overall, when comparing 
cases to controls, cases were 5.9‑fold significantly more 
likely to be diagnosed with an ASD than controls.
The results of the present study are consistent with 
those observed in the aforementioned study (current 
study risk=9.65 vs. previous study risk=5.9), but are dif‑
ferentiated in several important aspects. First, a longi‑
tudinal cohort study design was utilized in this study, 
whereas the aforementioned study utilized a cross‑sec‑
tional case‑control study design. Second, diagnoses 
generated from prospectively recorded medical records 
generated by healthcare providers on a longitudinal 
basis were examined in the present study, whereas the 
aforementioned study utilized comprehensive neuro‑
behavioral and cognitive follow‑up evaluations at spe‑
cific ages. Third, the present study examined gender, 
county of residence, and date of birth were considered 
as covariates in statistical models, whereas the afore‑
mentioned study did not examine covariates. Fourth, 
this study examined members of the cohorts for a much 
longer period of follow‑up (10 years) than the afore‑
mentioned study (5 years). The length of follow‑up is 
important because it can take many years for an ASD di‑
agnosis to become fully clinically apparent (Geier et al., 
2018), and studies that fail to consider this phenomenon 
may underestimate the true ASD diagnosis rate (Geier et 
al., 2013). Fifth, the current study evaluated the impor‑
tance of the age of an encephalopathy diagnosis on the 
long‑term risk of an ASD diagnosis, whereas the afore‑
mentioned study did not consider the age of an enceph‑
alopathy diagnosis. Finally, the present study examined 
time as a variable in the Cox proportional hazards mod‑
els constructed, whereas the aforementioned study did 
not. A simple comparison of the incidence rate of diag‑
nosed encephalopathy in the ASD cohort in comparison 
to the undiagnosed cohort revealed a significantly in‑
creased risk ratio=6.39 (95% confidence interval=5.76 to 
7.08) that was quite comparable to the risk=5.9 observed 
in the aforementioned study.
The results observed in this study also revealed 
that the age of an encephalopathy diagnosis is an 
important mediating factor on the long‑term risk of 
a child being diagnosed with an ASD. Specifically, it 
was observed that among those children diagnosed 
with an encephalopathy after the first year of life (ad‑
justed hazard ratio=12.30), the risk was significantly 
greater for an ASD diagnosis than for those children 
diagnosed with an encephalopathy within the first 
year of life (adjusted hazard ratio=3.65). As described 
previously, investigators hypothesized that many 
children diagnosed with an ASD undergo a progressive 
childhood encephalopathy associated with a develop‑
mental regression manifested by a loss of verbal, non‑
verbal, and social abilities starting at about 1 year‑old 
(Kern et al., 2013). The results observed in this study 
are supported by a number of other investigators ob‑
serving developmental regression in the second year 
of life among children subsequently diagnosed with 
an ASD. For example, investigators recently under‑
took a longitudinal study of children to examine the 
onset patterns of ASD (Ozonoff et al., 2018). These 
investigators described that regressive onset of ASD 
was observed on a prospective basis in 88% of children 
evaluated by medical examiners and in 69% as de‑
scribed by parents. The investigators concluded that 
a regressive onset pattern is common among children 
diagnosed with an ASD. Other investigators validated 
the phenomenon of regression among persons diag‑
nosed with an ASD by examining home videotapes 
(Werner et al., 2005).
Another important aspect of the findings of the 
present study was that it was possible to determine 
the risk difference (attributable rate) of encephalopa‑
thy in the ASD cohort. It was observed that 22.35% of 
persons in the ASD cohort were diagnosed with an en‑
cephalopathy, whereas only 3.50% of persons in the un‑
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diagnosed cohort were diagnosed with an encephalop‑
athy. As a consequence, the risk difference was 18.86% 
(95% confidence interval=16.67 to 21.04) for diagnosed 
encephalopathy in the ASD cohort. Therefore, almost 
1 out of 5 children diagnosed with an ASD were diag‑
nosed with an encephalopathy apparently attributably 
associated to their ASD diagnosis. This significant and 
common observation highlights the importance of 
brain damage (apparently manifesting as an encepha‑
lopathy diagnosis) in the etiology of an ASD for many 
children.
The results observed in the present study are bio‑
logically plausible. Brain pathology studies among 
persons diagnosed with an ASD indicate marked and 
ongoing inflammatory reactivity with concomitant 
neuronal damage, neurodegeneration and cerebral hy‑
poperfusion (Kern et al., 2013; Bjorklund et al., 2016; 
2018) rather than some type of developmental mishap 
of potential genetic or fetal origin (Bauman et al., 1997). 
A developmental mishap does not explain the extensive 
and consistent evidence of neuroinflammatory reactiv‑
ity, neuronal damage, and neurodegeneration which 
includes: activated microglia and astrocytes, elevated 
levels of glial fibrillary acidic protein, increased oxi‑
dative stress, elevated 8‑oxo‑guanosine levels, elevat‑
ed proinflammatory cytokines, aberrant expression of 
nuclear factor kappa‑light‑chain‑enhancer of activated 
B cells, and neuronal cell loss (Laurence and Fatemi, 
2005; Kern and Jones, 2006; Rodriguez and Kern, 2011; 
Kern et al., 2013).
One of the hallmarks of neuroinflammation and 
the potential for neurodegeneration is microglial ac‑
tivation. Microglial activation is reported in autism 
in many studies (Rodriguez and Kern, 2011; Kern et 
al., 2012; 2015; 2016). In addition, evidence indicates 
that the microglial activation in autism is sustained or 
chronic. Chronic microglial activation is implicated in 
the pathology of numerous neurodegenerative diseas‑
es including: Parkinson’s disease, Alzheimer’s disease, 
prion diseases, multiple sclerosis, and HIV‑dementia 
(Dheen et al., 2007; Lull and Block, 2010). Chronic mi‑
croglial activation can cause neuronal loss by directly 
attacking brain tissue, especially axons and synapses 
(Kern et al., 2016); however, microglial activation can 
also cause neuronal damage through the release of po‑
tentially cytotoxic molecules such as proinflammatory 
cytokines, reactive oxygen intermediates, proteinas‑
es and complement proteins (Dheen et al., 2007). Ev‑
idence suggests that the adaptive immune system can 
orchestrate an attack against central nervous system 
tissue by driving microglia to act like “Pac‑Man”, eat‑
ing up synapses, oligodendrocytes, neurons, and other 
healthy material (Zindler and Zipp, 2010; Piore, 2016). 
This process leads to cumulative neuronal loss over 
time (Lull and Block, 2010) and eventually becomes 
clinically evident.
The combined evidence in ASD is suggestive of 
a progressive childhood encephalopathy (Kern et al., 
2013). Encephalopathy, defined as a disease, damage, 
or malfunction of the brain, consists of various types, 
e.g., mitochondrial encephalopathy, hepatic encepha‑
lopathy, toxic encephalopathy, Hashimoto’s enceph‑
alopathy, metabolic encephalopathy, toxic‑metabolic 
encephalopathy, neonatal encephalopathy, etc. A re‑
cent review of the literature shows that the clinical 
manifestation of sequelae following insult can be de‑
layed from weeks to years. Therefore, it is biologically 
plausible for a childhood encephalopathy associated 
with developmental neurotoxicant exposures, especial‑
ly among males, could later manifest as ASD sequelae 
(Kern et al., 2017).
Strengths / Limitations
An important strength of this study was that retro‑
spective observations made in the IHRD were derived 
from eligibility and claims records prospectively gener‑
ated as part of the routine healthcare provided for per‑
sons in the Florida Medicaid system. Therefore, the data 
examined were generated completely separate from the 
current study design. The healthcare providers submit‑
ting claims for ASD and encephalopathy diagnoses were 
most likely not thinking about the possible relationship 
between ASD and encephalopathy diagnoses.
The study design utilized to examine the IHRD was 
another important strength of the present study. All 
persons examined in this study were eligible for Florida 
Medicaid from birth for 120 months (no gaps in eligibil‑
ity were allowed). In addition, in order to ensure that 
the cohort of persons examined was actively utilizing 
healthcare services from the Florida Medicaid system, 
all persons examined in this study had to have ≥ 10 out‑
patient office visit claims submitted (that averages to 
at least one outpatient office visit per person per year). 
These requirements helped to significantly reduce 
possible enrollment factors or difference in health‑
care‑seeking behaviors among the persons examined 
in this study.
Further, the diagnosis status was determined with 
precision for each person because detailed informa‑
tion regarding outcomes using ICD‑9 diagnosis coding 
and dates of service for claims submitted on behalf of 
each person were examined. In order for a person to 
be recognized as having an ASD diagnosis, the initial 
date of service specifying an ASD diagnosis was iden‑
tified. Similarly, in order for a person to be recognized 
as having an encephalopathy diagnosis, the initial date 
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of service specifying an encephalopathy diagnosis was 
identified.
Finally, the use of Cox proportional hazards sur‑
vival plot modeling to evaluate cases of encephalopa‑
thy diagnosed over a period of many years in the ASD 
diagnosed and undiagnosed cohorts allowed for us to 
draw inferences regarding the relationship between 
exposures and outcomes. Specifically, it was observed 
that the relationship was significant when considering 
the time variable in terms of person‑years of follow‑up. 
In order to further consider the Cox proportional haz‑
ards survival plot modeling results, logistic regression 
modeling was undertaken (no consideration of the 
time variable), and as revealed in Table V, the results 
remained significant for the risk of an encephalopathy 
diagnosis in the unadjusted (odds ratio=7.96) and ad‑
justed (odds ratio=7.46) models.
It is possible that a potential limitation of this study 
was that the findings observed were the result of statis‑
tical chance or cofounders/unknown biases in the data. 
Statistical chance seems unlikely given that a limited 
number of statistical tests were performed and most 
results were highly statistically significant. In addition, 
it was observed that the significant effects observed in 
unadjusted models remained significant even when 
adjusting for potential covariates such as gender, date 
of birth, and county of residence. The results observed 
this study were also consistent with previous epidemi‑
ological observations on different populations and are 
biologically plausible.
It is also be possible that some of the persons exam‑
ined in the IHRD may have had symptoms of enceph‑
alopathy that were so slight that they were not noted 
by their healthcare providers, or healthcare providers 
may have misdiagnosed or misclassified exposure sta‑
tus for some persons. Further, encephalopathy is an im‑
precise diagnosis, and, as such, there may be differenc‑
es in symptomology between persons. However, these 
potential limitations, while possible, should not have 
affected the results appreciably because it is uncertain 
how differential application would have occurred in 
the exposed and unexposed cohorts examined. Impor‑
tantly, any misclassification with respect to diagnostic 
or exposure status, would in all likelihood bias the find‑
ings towards the null hypothesis because persons ex‑
amined would have been put into the wrong exposure 
and/or diagnostic category, and result in diminished 
statistical power to establish the accurate relationship 
between exposures and outcomes.
Another potential limitation of the present study is 
that the underlying direct etiological basis for an ASD 
diagnosis was not examined. It was hypothesized that 
the results observed in this study were the result of 
a neuroinflammation‑associated progressive enceph‑
alopathy resulting in an ASD diagnosis. However, no 
direct brain pathological evidence was examined to 
support this hypothesis. It is recommended in future 
studies that direct brain pathological evidence be ex‑
amined among children diagnosed with an ASD. 
CONCLUSION
This retrospective cohort study of prospectively 
collected healthcare data from the IHRD provides new 
evidence that the incidence rate of childhood enceph‑
alopathy diagnoses are significantly more frequent in 
a cohort of children diagnosed with an ASD in compar‑
ison to a cohort of children not diagnosed with an ASD. 
Furthermore, the risk was greatest for persons diag‑
nosed with a childhood encephalopathy at >1 year‑old 
as compared to those diagnosed with a childhood en‑
cephalopathy at <1 year‑old. Finally, the IHRD based 
upon the results obtained in this study, is an important 
epidemiological resource to help quantitatively evalu‑
ate public health issues. 
Overall, the results of the present longitudinal epi‑
demiological study provide evidence that a significant 
Table V. Logistic regression model results examining the relationship between an encephalopathy diagnosis in the ASD diagnosed and undiagnosed cohorts.
Model Variable Odds Ratio 95% Odds Ratio CI p‑value χ2
I
ASD (Diagnosed vs. Undiagnosed) 7.96 6.99 to 9.07 <0.0001 975
II
ASD (Diagnosed vs. Undiagnosed) 7.46 6.54 to 8.52 <0.0001 888
Gender (Female vs. Male) 0.81 0.76 to 0.86 <0.0001 40
County of Residence 0.99 0.98 to 0.99 <0.0001 210
Date of Birth 1.00 1.00 to 1.00 0.86 0.03
Italicized results are statistically significant. Model I = unadjusted, Model II = adjusted for gender, county of residence, and date of birth. CI=confidence interval.
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number of children diagnosed with an ASD undergo 
a developmental regression as manifested by a child‑
hood encephalopathy diagnosis with an onset at >1 
year‑old. Future studies should further evaluate the re‑
lationship between childhood encephalopathy and ASD 
by determining potential postnatal factors contributing 
to childhood encephalopathy diagnoses.
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